Androgen resistance syndrome (AIS) is a genetic condition where the body’s cells cannot “hear” or respond fully to male-type hormones called androgens (like testosterone and dihydrotestosterone, DHT). A person with AIS usually has one X and one Y chromosome (46,XY), makes typical amounts of testosterone, but the body’s tissues do not react to it, so sexual development before birth and during puberty follows a more typically female pattern. AIS exists on a spectrum: complete (CAIS), partial (PAIS), and mild (MAIS). People with CAIS have typical female external genitals, no uterus, undescended testes, and infertility; PAIS varies; MAIS often looks male with infertility or gynecomastia. MedlinePlus+2MDPI+2
Androgen resistance syndrome—much more commonly called Androgen Insensitivity Syndrome (AIS)—is a condition where the body’s cells do not respond normally to androgens (the “male-type” sex hormones such as testosterone and dihydrotestosterone). A person with AIS almost always has 46,XY chromosomes (typically called “genetically male”) and working testes that make androgens, but their body cannot “hear” all or most of the androgen signal. Because the signal is blocked at the cell level, the genital organs and many body features develop along a spectrum—from a typical female appearance (complete AIS), to varied “in-between” appearances (partial AIS), to a typical male appearance with subtle issues such as infertility or breast growth (mild AIS). AIS is not caused by a lack of hormones; it is caused by the body’s tissues not responding to them. The problem usually comes from changes (pathogenic variants) in the AR gene, which makes the androgen receptor—the tiny “antenna” inside cells that listens to androgen signals. NCBI+2MedlinePlus+2
Other names
Androgen Insensitivity Syndrome (AIS) – the most accepted medical term today.
Complete Androgen Insensitivity Syndrome (CAIS) – cells do not respond to androgens at all (or almost not at all).
Partial Androgen Insensitivity Syndrome (PAIS) – cells respond a little; genital appearance varies widely.
Mild Androgen Insensitivity Syndrome (MAIS) – cells respond fairly well; issues can include infertility or gynecomastia.
46,XY differences/disorders of sex development due to AR – broader category name used in clinical guidelines.
Former term: “testicular feminization syndrome” – older, outdated name no longer preferred. NCBI+1
Types
Complete AIS (CAIS).
The body does not respond to androgens. External genitalia look typically female. There is no uterus. Testes are present but usually undescended (for example, in the groin or abdomen). Puberty brings normal breast development from estrogen made in the body, but little or no underarm or pubic hair. Menstruation does not occur, and fertility is not possible. Many people with CAIS are raised as girls and identify as women. MedlinePlus+1Partial AIS (PAIS).
The body responds only partly. Genital appearance at birth can range from mostly female to mostly male, with many mixes in between (for example, hypospadias, small penis, or enlarged clitoris). At puberty, breast development and hair patterns vary. Some people need surgeries or hormone care tailored to their body and identity. Orpha+1Mild AIS (MAIS).
The body responds mostly, but not fully. External genitalia usually look male at birth. Later, there can be gynecomastia (breast tissue in teens), reduced body hair, or infertility in adults. Diagnosis may happen only after fertility checking. NCBI
Causes
Important note: True AIS is caused by changes in the single gene called AR, which encodes the androgen receptor. The items below describe different ways that AR can be altered and how those changes interfere with androgen signaling. They are grouped as distinct mechanisms to help you understand how “cause” is interpreted in AIS. NCBI+1
Missense variants in the ligand-binding domain. A single “letter” change in the AR gene alters the receptor pocket that binds testosterone/DHT, making binding weak or impossible. Less binding = less signal. NCBI
Nonsense variants (premature stop codons). The receptor protein is cut short and cannot work. Cells become unresponsive to androgens. NCBI
Frameshift variants. Small insertions/deletions shift the genetic “reading frame,” producing a garbled receptor that fails to function. NCBI
Splice-site variants. The message that builds the receptor is mis-spliced; essential parts are skipped or added, creating a faulty receptor. NCBI
Large deletions in AR. One or more exons of the AR gene are missing, so the receptor cannot be made correctly. NCBI
Promoter or regulatory variants. Changes near AR lower how much receptor the cell makes, so the androgen “antenna” is too scarce to hear the signal. NCBI
Variants in the N-terminal transactivation domain. This part recruits helper proteins to “turn on” genes. If altered, the receptor reaches DNA but cannot switch on target genes. hormones.gr
Variants in the DNA-binding domain (zinc fingers). The receptor can bind hormone but cannot grab the DNA switch, so the message stalls. NCBI
Nuclear localization signal defects. The receptor cannot move efficiently into the cell nucleus after binding hormone, so signaling stops in the cytoplasm. hormones.gr
Dimerization defects. AR normally pairs with another AR to work. If the pairing site is altered, the “team” cannot form, cutting signaling efficiency. hormones.gr
Reduced stability or misfolding. Some variants make AR unstable; it is quickly degraded by the cell’s recycling system, so little receptor is available. hormones.gr
Weakened co-activator interactions. AR needs partner proteins (co-activators) to amplify the message. Variants that blunt these interactions lower output. (This is documented in functional studies for some AR variants.) hormones.gr
Aberrant post-translational modification sites. Changes at key phosphorylation/acetylation sites can disturb AR activation timing. hormones.gr
Mosaicism for an AR variant. Not all cells carry the same change; the mix can produce intermediate or patchy tissue response. NCBI
Germline AR variants inherited in an X-linked pattern. A mother who carries the AR change can pass it to a 46,XY child, who then manifests AIS. NCBI
De novo AR variants. The change appears for the first time in the child, with no family history. NCBI
Copy-number alterations involving AR. Rare rearrangements can disrupt AR structure or control regions, impairing function. NCBI
Altered androgen binding kinetics (reduced affinity). Some AR changes bind hormone weakly, so high hormone levels still trigger only a faint signal. NCBI
Defective receptor–chaperone interactions (e.g., HSP90). If AR cannot fold and travel properly, it never reaches its target genes effectively. hormones.gr
Compound heterozygosity or multiple AR variants in a family. Different changes in AR across relatives can explain varied severity within the same pedigree (from MAIS to PAIS to CAIS). NCBI
Common symptoms and signs
Symptoms can differ by age and type (CAIS, PAIS, MAIS). Not everyone has all features.
Typical female external genitalia in a 46,XY person (CAIS). Seen at birth; often no concerns until a groin hernia is found or puberty is unusual. MedlinePlus
Undescended testes (cryptorchidism), often in the groin or abdomen. May present as a painless lump in the labia/groin or as a childhood “hernia.” MedlinePlus
Absence of a uterus and cervix. The vagina is usually short and ends blindly. This is typically discovered in the teen years during work-up for no periods. MedlinePlus
Primary amenorrhea (no first period). A classic reason for evaluation in CAIS. MedlinePlus
Normal breast development at puberty in CAIS. Estrogens made from androgens drive breast growth, even though androgen actions are blocked. NCBI
Little or no pubic and underarm hair in CAIS. Hair growth depends on androgens, which tissues cannot sense. NCBI
Ambiguous or under-virilized genitalia in PAIS. May include hypospadias, small penis, bifid scrotum, or enlarged clitoris. Orpha
Gynecomastia in adolescence (MAIS/PAIS). Breast tissue can develop in teens assigned male at birth. NCBI
Reduced facial and body hair (PAIS/MAIS). Hair is an androgen-dependent trait. NCBI
Infertility (often MAIS; always in CAIS). Sperm production is commonly reduced or absent; pregnancy is not possible in CAIS. NCBI+1
Inguinal or labial masses in childhood. These are often testes in the groin; sometimes found during hernia surgery in children thought to be girls. NCBI
Short vagina in CAIS. Penetrative intercourse may be uncomfortable without counseling and options such as dilation therapy or surgery if desired. NCBI
Psychosocial stress and identity questions. People and families may need sensitive, ongoing support and age-appropriate information. Oxford Academic
Bone health concerns after gonad removal. Estrogen replacement is important; bone density should be monitored. NCBI
Variable virilization at puberty in PAIS. Voice deepening, muscle bulk, and genital changes may be partial or inconsistent. Orpha
Diagnostic tests
In practice, doctors combine the story, exam, hormone tests, chromosome tests, imaging, and AR gene testing to make or exclude a diagnosis. Below are common tools grouped by category. Not every test is needed for every person. NCBI+1
A) Physical examination (bedside assessments)
General newborn or teen exam focused on sex development. The clinician looks at genital anatomy, body hair, breast development, height, and any groin masses to decide which tests to order next. NCBI
External masculinization score (EMS) or Prader scoring. Simple clinical scales help describe how virilized the external genitalia are; this helps narrow the diagnosis among 46,XY DSD conditions. PMC
Inguinal and labial palpation. The examiner gently feels for undescended testes or hernias in infants and children, which are common clues in CAIS. NCBI
Tanner staging at puberty. The clinician records breast stage, pubic hair stage, and genital development to see how puberty is progressing without androgen action. NCBI
Focused gynecologic/urologic exam (age-appropriate). In teens or adults, a careful, sensitive exam may assess vaginal length, openings, or hypospadias to guide imaging and treatment planning. NCBI
B) “Manual” clinical tools (simple bedside procedures and measurements)
Stretched penile length or clitoral size measurement (in PAIS). Objective measurements track growth over time and response to any therapy. Oxford Academic
Orthopedic and breast measurements related to puberty changes. Documentation (for example, gynecomastia size) helps assess androgen effect vs. estrogen effect. NCBI
Pelvic exam with gentle dilator sizing (in consenting adults with CAIS). This is sometimes used during non-surgical vaginal dilation therapy planning and is performed respectfully and only if desired. NCBI
Note: These “manual” items are simply hands-on clinical assessments; they do not diagnose AIS by themselves but help tailor testing and care. Oxford Academic
C) Laboratory and pathological tests
Karyotype (chromosome test). Confirms 46,XY (typical in AIS). This anchors the evaluation of 46,XY differences in sex development. NCBI
Hormone panel at baseline (LH, FSH, testosterone, DHT). In AIS, testosterone is normal or high, often with elevated LH, because the body tries to push the unresponsive system harder. NCBI
Anti-Müllerian hormone (AMH) and inhibin B. These markers, made by testicular cells, help show testicular presence and function, especially in children. NCBI
hCG stimulation test (in infants/children). hCG prompts the testes to make more testosterone; the response helps separate AIS (normal T production) from androgen biosynthesis defects (low T production). NCBI
T:DHT ratio or DHT response. Helps exclude 5-alpha-reductase deficiency (a different condition); in AIS this ratio is usually normal. NCBI
AR gene sequencing (molecular test). The most direct test: looks for a pathogenic AR variant causing AIS. Panels or exome sequencing may also be used. NCBI
Copy-number analysis (e.g., MLPA). Detects larger AR deletions/duplications that regular sequencing can miss. NCBI
(Rarely needed) Androgen binding/functional assays in cells. Specialized labs can test how well AR binds hormone or activates genes, mainly in research or complex cases. hormones.gr
D) Imaging tests
Pelvic/inguinal ultrasound. Looks for testes in the groin/abdomen and checks for the absence of a uterus. First-line imaging in children. NCBI
MRI pelvis/abdomen. Gives more detail about gonad location and internal anatomy to guide surgery decisions. NCBI
Genitography or endoscopy (selected cases). Contrast studies or endoscopic inspection can outline internal channels if surgical planning is needed. Oxford Academic
Bone mineral density (DXA) after gonad removal or in long-term care. Tracks bone health and guides hormone replacement to protect bones. NCBI
Non-pharmacological treatments (therapies & others)
Multidisciplinary DSD team care – coordinated visits with endocrinology, gynecology/urology, psychology, genetics, and specialized nursing improve understanding, reduce anxiety, and support shared decisions over time. Purpose: whole-person care. Mechanism: integrated expertise and counseling. Oxford Academic
Genetic counseling – explains the AR gene change, inheritance (often X-linked), recurrence risk, and options for relatives who want testing. Purpose: informed family planning. Mechanism: risk assessment and education. MedlinePlus
Psychological support & peer groups – common needs include coping with diagnosis, identity, intimacy, and stigma. Professional counseling and peer communities improve quality of life. Purpose: mental well-being. Mechanism: evidence-based psychotherapy and social support. NCBI
Informed decision-making about gonads – CAIS has low prepubertal tumor risk; many teams delay gonadectomy until after puberty so natural puberty can occur, then revisit choices with the patient. Purpose: balance tumor risk with benefits of endogenous puberty. Mechanism: staged, consent-based counseling. e-apem.org+1
Surveillance when gonads retained – if the person chooses to keep gonads, teams discuss regular clinical review and imaging (e.g., ultrasound/MRI) to watch for changes. Purpose: early detection. Mechanism: risk-based monitoring pathways. PMC
Vaginal self-dilation (first-line for a short vagina) – gentle, structured use of dilators can lengthen the vagina without surgery, with >90–96% success when the person is ready and supported. Purpose: comfortable intercourse if desired. Mechanism: tissue expansion by gradual pressure. ACOG+1
Sexual-health education – practical advice on lubrication, pacing, comfort, consent, and pleasure; addresses dyspareunia and expectations. Purpose: satisfying, safe sex. Mechanism: skills and knowledge. ACOG
Pelvic floor physical therapy – teaches relaxation and coordination for comfort with dilation or intercourse; helpful for vaginismus. Purpose: reduce pain, improve function. Mechanism: biofeedback and graded exposure. PMC
Bone-health lifestyle plan – weight-bearing/resistance exercise, fall-prevention, not smoking, and limiting alcohol to protect bone density, which can be low in AIS. Purpose: reduce osteoporosis risk. Mechanism: mechanical loading and risk-factor reduction. PMC+1
Nutrition coaching for bones – food-first calcium and vitamin D, protein adequacy; supplements only to fill gaps per guidelines. Purpose: support bone remodeling. Mechanism: optimize mineral and protein intake. Bone Health & Osteoporosis Foundation
Sunlight & vitamin D literacy – safe sun practices and vitamin D intake aligned with current endocrine guidance. Purpose: maintain 25(OH)D in a healthy range. Mechanism: skin synthesis + diet/supplements per need. Endocrine Society+1
Fertility and family-building counseling – CAIS lacks eggs/uterus, so options are adoption or gestational carrier with donor eggs if desired. Purpose: plan pathways to parenting. Mechanism: reproductive counseling and legal guidance. PubMed
Body-image and identity support – structured sessions normalize variation, address hair pattern, chest, genital differences, and social issues. Purpose: self-esteem and well-being. Mechanism: CBT, ACT, and affirming care. NCBI
Transition-of-care planning – smooth handoff from pediatric to adult services to maintain hormone care, bone checks, and sexual health follow-up. Purpose: continuity and safety. Mechanism: planned transition protocols. Oxford Academic
Cancer-risk education – clear, age-appropriate explanation that CAIS tumor risk is low before puberty and increases with age, with shared planning for surveillance or surgery. Purpose: reduce fear, guide choices. Mechanism: evidence-based risk framing. e-apem.org
Pain and hernia care – inguinal hernias or gonadal pain are managed conservatively or surgically depending on symptoms. Purpose: comfort and safety. Mechanism: individualized surgical consultation. Children’s Hospital of Philadelphia
Education on medications & adherence – practical coaching to take estrogen consistently after gonadectomy to protect bones and well-being. Purpose: prevent osteopenia and symptoms. Mechanism: adherence strategies. PMC
Community and advocacy connections – linking with AIS/DSD support groups improves knowledge and resilience. Purpose: reduce isolation. Mechanism: peer modeling and shared experience. Endocrine Society
General preventive care – routine vaccines, STI prevention, cardiovascular risk screening (as with any adult on hormones), and cervical screening is not needed when there is no cervix. Purpose: overall health. Mechanism: age-appropriate prevention. NCBI
Shared documentation – providing letters that clearly explain AIS can reduce confusion in emergency or travel situations. Purpose: smoother care journeys. Mechanism: concise medical summaries. Oxford Academic
Drug treatments
In AIS, medicines focus on puberty support, bone health, and symptom goals. Not every drug fits every person. Always individualize with your clinician.
Transdermal 17β-estradiol (patch) – a common first-choice after gonadectomy or if endogenous estrogen is inadequate. Purpose: sustain feminization, protect bone, reduce vasomotor symptoms. Mechanism: physiologic estradiol delivery; some data suggest transdermal may have metabolic advantages. Typical adult maintenance often equals 50–100 μg/day patch, titrated. The Lancet
Oral 17β-estradiol – alternative to patches for estrogen replacement; dose individualized (e.g., 1–4 mg/day equivalents). Purpose/mechanism: as above. PMC
Estradiol gel – topical route for those preferring gels; titrated to clinical targets. Purpose: flexible dosing without first-pass liver effect. Mechanism: transdermal absorption. The Lancet
Ethinyl estradiol – effective but generally less favored long-term compared with 17β-estradiol in many centers due to hepatic effects; may be used in some puberty-induction protocols. Purpose: puberty induction/maintenance where chosen. Mechanism: potent oral estrogen. archivesofmedicalscience.com
Testosterone therapy (selected adults with CAIS post-gonadectomy) – emerging evidence shows testosterone may be non-inferior to estradiol for quality of life and yields similar estradiol levels via aromatization; used when patients prefer. Doses individualized (e.g., transdermal). Purpose: symptom control and well-being. Mechanism: aromatization to estradiol; limited AR action in CAIS. SpringerLink
Topical dihydrotestosterone (DHT) gel – in some PAIS assigned-male infants/children to address micropenis before surgery or at puberty. Purpose: local androgen effect. Mechanism: non-aromatizable androgen acting on partially responsive tissues. Evidence is limited and case-based. NCBI
Testosterone (systemic) in PAIS assigned male – supports pubertal virilization where tissues retain partial sensitivity. Purpose: develop secondary male traits. Mechanism: AR stimulation where functional. NCBI
Vaginal estrogen cream – short-term adjunct to improve comfort with dilation/intercourse if tissues are dry or fragile. Purpose: local comfort. Mechanism: local mucosal trophic effects. ACOG
Calcium supplementation – only if intake is below targets after a food-first approach. Typical total daily calcium (food + supplements) 1,000–1,200 mg depending on age/sex. Purpose: bone mineral support. Mechanism: mineral substrate. Bone Health & Osteoporosis Foundation
Vitamin D3 supplementation – dose per guideline (often 400–1,000 IU/day in healthy adults; higher in selected groups); check local policy. Purpose: enhance calcium absorption and bone health. Mechanism: 25(OH)D sufficiency. Endocrine Society+1
Bisphosphonates (e.g., alendronate) – considered for confirmed osteoporosis/fracture risk after specialist review; not first-line for otherwise healthy young adults if HRT is optimized. Purpose: reduce fracture risk. Mechanism: inhibit bone resorption. PMC
Denosumab – specialist option for high-risk osteoporosis when indicated. Purpose: fracture prevention. Mechanism: RANKL inhibition. PMC
Selective estrogen receptor modulators (SERMs) – niche use in bone health; balance risks/benefits; not routine in AIS. Purpose: bone density support in selected cases. Mechanism: ER agonism in bone. PMC
Analgesics (short-term) – for post-op or dilation-related pain per general standards. Purpose: comfort. Mechanism: nociception modulation. NCBI
Topical lubricants/moisturizers – non-hormonal products to reduce friction and dryness during dilation or sex. Purpose: comfort and tissue protection. Mechanism: barrier and hydration. ACOG
GnRH analogues – not routine for CAIS; in selected PAIS scenarios may be used to modulate puberty timing or symptoms, under specialist care. Purpose: tailored endocrine control. Mechanism: pituitary down-regulation. NCBI
Anti-androgens – generally not useful in CAIS (receptor nonfunctional); very selective PAIS scenarios may consider them for symptom control, but they are not standard. Purpose: reduce androgen effects when unwanted. Mechanism: AR blockade. NCBI
Iron and B12 (if deficient) – treat documented deficiencies that worsen fatigue; not AIS-specific. Purpose: correct anemia and energy. Mechanism: replace nutrient deficits. Office of Dietary Supplements
Psychotropic meds – only if clinically indicated for co-existing anxiety/depression; psychotherapy remains first-line. Purpose: mental health support. Mechanism: neurotransmitter modulation. NCBI
All medications are individualized – choices depend on age, anatomy, goals, tumor-risk decisions, bone status, and side-effect profiles. Purpose: person-centered safety. Mechanism: shared decision-making. Oxford Academic
Note on progesterone: In CAIS there is no uterus, so routine progesterone is not required; some publications discuss combined therapy, but there’s no clear benefit and potential downsides—most expert sources use estradiol alone. PMC+2MDPI+2
Dietary molecular supplements
Vitamin D3 (cholecalciferol): supports calcium absorption and bone mineralization; dose per guideline and blood levels. Endocrine Society+1
Calcium (as citrate/carbonate): fill gaps to reach total daily targets (usually 1,000–1,200 mg/day from diet + pills). Take with food if carbonate. Bone Health & Osteoporosis Foundation
Protein (whey/food): adequate protein helps bone and muscle; aim for balanced intake via diet, supplement only if dietary intake is low. NIAMS
Magnesium: co-factor in bone metabolism; emphasize dietary sources (nuts/greens), supplement only for proven shortfall. Office of Dietary Supplements
Vitamin K (esp. K2): supports bone proteins; prioritize leafy greens/fermented foods; supplements considered case-by-case. Office of Dietary Supplements
Omega-3 (fish oil): general anti-inflammatory benefits; food (fatty fish) preferred; consider capsules if intake is low. World Health Organization
B12 & Folate: correct documented deficiencies affecting energy and homocysteine (bone risk factor); common in restricted diets. Office of Dietary Supplements
Zinc: supports general health; avoid high-dose chronic supplements; emphasize diet first. Office of Dietary Supplements
Boron (trace): possible role in mineral metabolism; keep to dietary sources; supplements only with specialist advice. Office of Dietary Supplements
Electrolyte-balanced hydration: not a pill, but maintaining calcium/sodium balance and avoiding excess soda may help bone. Bone Health & Osteoporosis Foundation
Immunity-booster / regenerative / stem-cell drugs
There are no approved immune-booster, regenerative, or stem-cell drugs for AIS. AIS is due to an AR gene receptor problem; there is currently no gene repair, stem-cell, or regenerative medicine proven to restore AR function in humans. Management remains supportive (hormones, counseling, selective surgery, bone care). Promising basic research exists, but no clinical therapy of this kind is available—using unproven products can be risky and expensive. Safer alternatives are the non-pharmacologic and hormone options above, delivered by a DSD-experienced team. Wikipedia+1
Surgeries
Gonadectomy (orchiectomy) – removal of undescended testes after puberty in many CAIS patients, or earlier in selected cases, to address age-rising tumor risk and personal preference. Risks and timing are individualized; some choose surveillance instead. e-apem.org
Hernia repair ± gonad management – repairs inguinal hernias; gonads may be removed, repositioned (orchiopexy), or left with surveillance depending on plans and risk. Children’s Hospital of Philadelphia
Vaginal surgery (neovaginoplasty) – usually not first-line because dilation works in >90–96%; surgery is reserved for those who prefer it or do not succeed with dilation, with ongoing dilation post-op. ACOG
Hypospadias and genital reconstruction (PAIS, assigned male) – staged procedures to improve urinary/sexual function and match individual goals; timing is carefully discussed. NCBI
Chest surgery (rare in PAIS males with severe gynecomastia) – reduction mammoplasty if significant symptoms persist. NCBI
Practical preventions
Keep hormone therapy optimized after gonadectomy to protect bones and well-being. PMC
Regular bone health plan: exercise, calcium/vitamin D, and DXA scans when advised. PMC+1
Smoking cessation & limit alcohol to reduce bone loss. PMC
Shared decision-making for any surgery—no rushed procedures. Oxford Academic
Cancer-risk conversations and, if retaining gonads, agreed surveillance plan. PMC
Injury/fall prevention during exercise; use progressive resistance with instruction. NIAMS
Sexual-health literacy (lubrication, consent, STIs) and pelvic physiotherapy if pain arises. ACOG
Vaccinations and routine primary care like anyone else. NCBI
Mental-health and peer support for resilience and coping. NCBI
Keep personal medical summary for ER or travel. Oxford Academic
When to see a doctor
New groin/abdominal mass, pain, or swelling if you have undescended gonads or retained testes. PMC
Unexplained bleeding, fever, or severe pelvic pain after dilation or surgery. ACOG
Hot flashes, night sweats, mood changes, low energy, or bone pain if you’ve had gonadectomy—may signal estrogen under-replacement. PMC
Before starting or changing hormones/supplements, to tailor doses safely. The Lancet
Any mental-health concerns (anxiety, depression, relationship stress). NCBI
What to eat & what to avoid
Emphasize: calcium-rich foods (dairy, tofu set with calcium, leafy greens), vitamin-D sources (oily fish, fortified foods), adequate protein (eggs, fish, legumes), and a colorful plant-forward pattern for heart and gut health. Limit alcohol, excess sodium, and sugar-sweetened beverages; avoid smoking. Most people should meet calcium needs from food and add vitamin D only as needed per guideline. Bone Health & Osteoporosis Foundation+1
FAQs
1) Is AIS the same as “testicular feminization”?
Yes—“testicular feminization” is the old name; today we use androgen insensitivity syndrome (AIS). Cleveland Clinic
2) Can AIS be cured?
No curative gene or receptor fix exists yet; treatment focuses on hormones, selective surgery, and supportive care. Wikipedia
3) Do people with CAIS need periods or progesterone?
No uterus = no periods and no routine progesterone requirement. PMC+1
4) Is gonad removal always required?
Not always. Prepubertal risk is low in CAIS; many defer until after puberty. Others choose surveillance. Decisions are shared and individualized. e-apem.org
5) Can someone with CAIS get pregnant?
No eggs and no uterus, so pregnancy is not possible; family-building options include adoption or gestational carrier with donor oocytes. PubMed
6) Why is bone health a big topic in AIS?
Some people with AIS have low bone mineral density, especially if estrogen is inadequate or gonads were removed without proper HRT. PMC
7) Which estrogen is best?
Most centers favor 17β-estradiol (patch or oral). Routes are individualized; transdermal can have metabolic advantages. The Lancet
8) Can testosterone be used after gonadectomy in CAIS?
Some adults prefer testosterone, and trials suggest similar quality of life vs estradiol (aromatization produces estradiol). It’s a valid, shared decision. SpringerLink
9) Does dilation hurt?
With good teaching, lubricants, and pacing, most people succeed and can keep discomfort low; surgery is second-line. ACOG
10) What about hair patterns?
Sparse pubic/axillary hair is typical in CAIS because hair follicles need androgens. This is normal and harmless. MedlinePlus
11) Is gender identity predictable in AIS?
Most with CAIS are raised female and identify as women, but identity is personal. Care is supportive and non-coercive. Oxford Academic
12) Are there cancer screening tests if I keep my gonads?
Teams may offer periodic exam and imaging; there’s no perfect test, so decisions weigh benefits and burdens. PMC
13) Do supplements replace hormones?
No. Calcium/vitamin D support bone, but do not replace estrogen’s key role after gonadectomy. PMC
14) Can surgery “create” a uterus?
No. Surgery can create a vaginal canal if desired, but it cannot create a functioning uterus. ACOG
15) Where can I read more?
Authoritative overviews: GeneReviews, MedlinePlus Genetics, Endotext, and the Endocrine Society guidance for DSD care.
Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.
The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members
Last Updated: September 17, 2025.
